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Comparisons can be odious 
T. BETTS 
When I first started working in the field of 
epilepsy, over 25 years ago, therapeutic options 
were much more limited than they are today. 
Surgery had not yet reached an established place 
in the management of intractable epilepsy and the 
pharmaceutical industry seemed little interested 
in producing better drugs for treating the 
condition with fewer side-effects. By comparison, 
with the pressure today to use new drugs, the 
manufacturers who had just introduced car- 
bamazepine and sodium valproate for the treat- 
ment of epilepsy seemed almost apologetic about 
their products. Extensive double blind clinical 
trials and evidence based medicine were very far 
away. The almost daily visits of keen drug 
representatives extolling the virtues of his or her 
anticonvulsant which we experience nowadays 
did not occur. 
We were left much more to our own en- 
deavours and gradually learned to use the new 
anticonvulsants, discovering for ourselves both 
their virtues and their drawbacks, developing a
clinical practice with them based largely on our 
own experience and the experience of colleagues 
that we trusted. My mentor, for instance, was 
Peter Jeavons who taught me to use valproate in 
his own unique way (using weight related doses, 
monitoring EEG responses as a guide to sufficient 
dosage and totally .ignoring blood levels). Like- 
wise I learned the value from him of low, slow 
dose escalations of carbamazepine (so low and 
slow in fact that I have never personally caused a
carbamazepine rash). 
I was learning my epilepsy skills in the 
seventies. Part of my research at that time was to 
study the effect of various prescribed rugs on 
cerebral function--particularly their effects on 
mood and psychomotor performance ( specially 
as related to their possible detrimental influence 
on driving skills). As a result, for some time, I 
rubbed shoulders with physicians in the hyper- 
tension field at a time when there was a sudden 
surge in interest in the management of hyperten- 
sion with somewhat less poisonous compounds 
than we had used previously; particularly the beta 
blocking drugs which were competing actively 
with each other to be the best antihypertensive 
with fewest side-effects. 
Debate raged as to whether lipid solubility was 
better than water solubility. Was some ISA 
activity necessary in your beta blocker? Was it 
better to have a beta blocker that penetrated the 
central nervous ystem or one that did not? Was 
Beta 2 activity a good thing or not? Debate, 
claims and counterclaims, were endless. As what 
seemed like dozens of compounds, all with 
slightly different properties, hit the market, polite 
young men and women in suits tried to persuade 
us of the outstanding virtues of their own 
particular product. At cardiological meetings 
endless Satellites were held in which men in 
slightly more expensive suits (the opinion leaders 
so beloved of the pharmaceutical industry) held 
forth about the virtues of different types of beta 
blocker. A plethora of pens, notepads and other 
little gifts suddenly appeared on doctors' desks all 
discretely labelled with the trade name of a 
particular beta blocker. 
Perhaps the competition of these heady days 
was a waste of money and resources but it did 
lead in its own insidious way to a great deal of 
basic research into the mechanisms of hyperten- 
sion itself, which eventually led to better drugs 
with fewer side-effects and better understanding 
of the whole process of hypertension and some 
insight into the quality of life of people taking 
drugs for very long periods of time to control 
blood pressure. For the first time physicians did 
not treat hypertension as though they were just 
treating a column of mercury but began to think 
about the person with the raised blood pressure. 
Epileptologists are now, fairly suddenly, being 
exposed to a similar kind of pressure. In the last 
five years Several new compounds have emerged, 
(one or two to disappear almost as quickly as 
they had arrived) but some clearly becoming 
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established and fighting for a place in the 
anticonvulsant market. Polite young women and 
men (still in suits) are appearing in our consulting 
rooms extolling the virtues of a particular new 
anticonvulsant: competing claim succeeds com- 
peting claim. 
But a new element has entered into this world. 
Back in the seventies it never crossed my mind to 
wonder how much the drugs we were using 
actually cost. I was actually much freer to make 
my own decisions about which drug was going to 
be of particular benefit to a particular patient. 
Now we all have to think of health costs. The new 
drugs are much more expensive than the old. 
Again young men and women (still in suits--the 
new managers) are now monitoring the cost of 
epilepsy health care and beginning to question 
whether we should be using the new compounds 
at all since they are perhaps at least ten times as 
expensive as the old. Some of our colleagues 
make a virtue of cost consciousness byusing it to 
justify their therapeutic conservatism. Yet other 
young men and women (still in suits--since they 
are mostly psychologists) are now teaching us to 
ask different questions about our medication: ot 
just in terms of how effective it is but whether it 
improves patients' quality of life. 
Even neurologists, who are perhaps the most 
conservative of us, are now talking earnestly 
about quality of life and its measurement. So 
converted are they to the notion of improving 
'Quality of Life' that they are beginning to talk 
and write as though they invented it, thus causing 
wry amusement amongst psychiatrists who have 
been writing on the topic for at least the last 50 
years and have been paying more than lip service 
to it. 
One of the problems for the manufacturers of 
new antiepileptic ompounds is that their de- 
velopment isextremely slow. Manufacturers must 
look back in envy to the days when phenytoin was 
synthesized, tested and put onto the market 
within about three years. Nowadays it may be 
10-12 years before a drug is licenced to go on the 
market and vast sums have been spent on 
rigorous afety and efficacy testing before it does. 
Another problem is that the efficacy of the drug is 
tested on a population of patients with chronic 
partial seizures who are resistant to conventional 
medication and who are not suitable (or are 
waiting) for surgery. A manufacturer who is just 
star.ting to test his new compound today is 
therefore faced with carrying out these tests on a 
group of patients who may already have failed 
with phenytoin, carbamazepine, sodium valpro- 
ate, vigabatrin, lamotrigine, gabapentin, topiram- 
ate and tiagabine and probably therefore are 
resistant o anything they are ever likely to be 
offered. 
It seems to me that an expanding army of new 
anticonvulsants is chasing a diminishing uerilla 
band of resistant patients: their numbers lessen- 
ing with every new successful compound. In 
clinics like mine how many patients can be found 
who regularly have at least four partial seizures a
month and are prepared to undergo extensive 
baseline monitoring? Most such patients nowa- 
days are only to be found in the ranks of the 
learning impaired who are excluded from most 
trials. Some manufacturers are starting to con- 
template doing initial trials in the economically 
disadvantaged parts of the world (with all the 
logistical and ethical problems uch an approach 
brings with it) as the supply of suitable patients in 
the western world dries up. 
We have to fall back on statistical manipulation 
of data to show that a significant number of trial 
patients had a 50% reduction in seizure .frequency 
compared with placebo thus 'proving' that the 
drug is probably effective (whereas clinicians-- 
and patients--are more concerned with how 
many patients in the trial became seizure free). 
Doses used are often mere guesswork: because 
the patients are so resistant and so enzyme- 
induced, the chosen dose may have no relation- 
ship at all to the effective dose in a patient 
population that is not resistant to anticonvulsants. 
Very few of the resistant group of patients are 
likely to become seizure free on the drug and if 
they do their freedom from seizures may be 
short-lived. 
Showing a drug to be effective in properly 
conducted ouble blind placebo controlled trials 
may tell us very little about how effective the drug 
is going to be in the population of patients we 
normally treat. Eventually of course the new drug 
comes into direct competition with an older 
standard rug (usually carbamazepine) ona head 
to head basis in a monotherapy trial in patients 
with newly established seizures. 
Such monotherapy trials do not usually have a 
placebo condition in them although I have more 
than a sneaking suspicion that placebos might do 
very well in such trials (particularly because we 
know that at least 30% of people who start having 
epilepsy will lose it for themselves without 
needing any medication). It is easy to uninten- 
tionally manipulate the results of monotherapy 
trials with new compounds particularly if one is 
measuring quality of life and side-effect profiles as 
well. One such recent trial I was asked to take 
part in involved a starting dose of the comparator 
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carbamazepine that was so high that I would not 
have been surprised if every patient dropped out 
of the carbamazepine arm of the trial almost 
immediately due to side-effects. The dose of the 
new drug was much lower than the one used in 
the add-on double blind trials that had preceded 
this particular trial. Was this to minimize 
side-effects? I declined the invitation to take 
part in this trial and I am not certain it went 
ahead. 
Therefore it is often not until the drug has 
actually got onto the market that one really 
begins to learn in what group of patients it is 
effective, what its side-effects are and what dose is 
actually needed to produce a reasonable ffect. 
This is why results of open trials (although 
derided by some) can be useful. Providing careful 
records are kept and careful audit made of the 
clinician's experience the results of such trials can 
be helpful as a guide to other clinicians who are 
starting to use the drug in question. 
When the drug has been on the market for a 
few years it can be helpful to present careful audit 
of its use in particular clinics which again may 
give some indication as to wheter it really fits into 
the therapeutic profile. 
We are certainly prepared in Seizure to publish 
careful audits of the clinical use of new com- 
pounds providing that relevant data has been 
collected properly and that the audit is presented 
(as double blind trials are presented) on an 
'intention to treat' basis. We recently rejected an 
audit paper of one of the new compounds (which 
gave it a very favourable impression). The audit 
was trying to establish whether tolerance de- 
veloped to the initial beneficial effects of this 
particular compound. Unfortunately this particu- 
lar audit did not commence until the patients had 
been taking the new drug for at least six months 
and therefore ignored those patients who started 
it but who subsequently stopped taking it fairly 
rapidly (for various reasons), thus skewing the 
results of the audit to favour the drug. 
What one has yet to see in the scientific 
literature are proper head to head comparisons 
between the new compounds themselves. If 
tested head to head in a comparable population 
would vigabatrin really be more powerful than 
lamotrigine but have more side-effects? Would 
gabapentin be less powerful than lamotrigine but 
have fewer side-effects? We need to establish the 
scientific answer to these questions particularly 
because as competition hots up between the new 
compounds (and as the young men and women in 
their suits become more vociferous in persuading 
us that their particular compound is better) we 
are reaching aposition where invidious and unfair 
comparisons are being drawn between the new 
compounds based on the results of earlier double 
blind trials in resistant patients. Recently the sales 
pitch of one particular new compound suggested 
that it was superior to other new compounds 
because meta analysis of its trials in resistant 
patients howed that significantly more patients 
reached the 'magic' figure of 50% seizure 
reduction in its trials than in comparable trials of 
its competitors: o therefore this drug should be 
the logical first line add-on drug. 
I think we should not be taken in by this--like 
is not being compared with like. The relative 
proportion of patients in the various trials who 
had partial seizures only or who had partial 
seizures with secondary generalization was 
different: he higher the proportion of the latter in 
a clinical trial the more likely it is that there will 
be a better result. How many patients in 
lamotrigine trials were already vigabatrin resis- 
tant? How many in gabapentin trials were already 
vigabatrin and lamotrigine resistant? Were pati- 
ents in topiramate trials naive to exposure to the 
other new compounds? These factors will very 
much affect he outcome of a trial. Only head to 
head trials should be used for direct comparisons 
between the new drugs. 
Even if direct head to head comparisons are 
made, efficacy in seizure control is not the whole 
issue: quality of life and side-effect profile are 
equally important and must also be addressed. 
Some clinicians engaged to speak in Satellite 
Symposia on the relative efficacy of the new 
anticonvulsants are beginning to draw up league 
tables of efficacy and are beginning to suggest that 
certain of the new compounds should be the first 
add on compound in patients whose epilepsy is 
resistant to conventional medication. Most such 
league tables seem to concentrate on anticonvul- 
sant efficacy and ignore side-effects (with the 
exception of Martin Brodie's Star System). Most 
patients, however, offered the choice between 
two drugs, one of which had 10% better efficiency 
but more side-effects and another which was 
potentially less efficient but had fewer significant 
side-effects, would probably choose the latter 
(rather than be told what to take by an imperious 
specialist who has never had to make the choice 
personally). Should We also have league tables for 
men and women separately? A particular drug 
might be the logical first choice add-on drug but if 
it is teratogenic it surely cannot be so for women 
of child bearing potential? 
We publish in this issue of Seizure a different 
type of comparison of new compounds based on 
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economic rather than clinical criteria: cost rather 
than just efficacy. This paper is likely to be 
controversial nd not everyone will agree with it, 
but our referees feel that it is worth publishing if 
only to invite comment and discussion. Because 
this is an economic rather than a clinical paper it 
makes certain assumptions about the three new 
compounds it is evaluating particularly in terms of 
their clinical efficacy. It also makes assumptions 
about the clinical doses of these compounds and 
the consequences of management, and the 
seriousness of, side-effects which not everybody 
will agree with. I felt, after some consideration, 
that this paper was worth publishing for your 
consideration and to promote discussion about 
whether cost should be a consideration that we 
should take into account when considering the 
efficiency of new antiepileptic compounds. In this 
era of intense competition between manufac- 
turers of antiepileptic drugs (which we have never 
experienced before) we need to be able to make 
our own informed judgments. 
